[Botulinum toxin for the treatment of headache]

Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Romano M
Record ID 32014000327
Authors' objectives: Evaluate the available evidence about the effectiveness, safety and insurance policy related to the use of TBA in patients with ME. MC, CST.
Authors' recommendations: TBA has not been proved to be superior to placebo for the prophylaxis treatment of chronic headache tension or episodic migraine. In general, its use is endorsed among patients who meet the criteria for chronic migraine set by the International Headache Society and who have failed or have intolerance of contraindications to other prophylactic agents. It should be noted that the benefit seen in studies in patients with CM , who promoted its adoption by the FDA and the various regulatory agencies was of low magnitude. These benefits include a reduction of -2.3 headache episodes per month compared to a baseline of 12, or in secondary outcomes (reduction in the number of headache days per month) -1.5 with a baseline of 20 days. These results, more than being statistically significant, are clinically irrelevant, implying a significant cost.
Project Status: Completed
Year Published: 2011
URL for published report: www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Botulinum Toxins
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.